Advertisement

ADVERTISEMENT

prostate cancer

From the Field
Incidence and Cost of Radical Prostatectomy and Radiotherapy for NCCN Low-risk Prostate Cancer in Utah
03/16/2022
David Gill, MD
Jessica Baumgartner
Jesse Gygi
McKenzie Bell
Libby Petersen
Bryan Crawford
Zoya Sandhu
Brandon Barney, MD
Jonathan Tward, MD
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues...
03/16/2022
Journal of Clinical Pathways
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
02/24/2021
02/24/2021
Journal of Clinical Pathways
News
Health Care Spending for High-Resource Patients With Prostate Cancer
02/01/2021
02/01/2021
Journal of Clinical Pathways
News
Real-World Costs of First-Line Prostate Cancer Management Strategies
01/05/2021
01/05/2021
Journal of Clinical Pathways
FDA Approves Relugolix for Advanced Prostate Cancer
FDA Alerts
FDA Approves Relugolix for Advanced Prostate Cancer
12/18/2020
12/18/2020
Journal of Clinical Pathways
News
Clinical Pathway Modification Increases Adoption of Hypofractionated RT for Prostate Cancer
12/17/2020
12/17/2020
Journal of Clinical Pathways
News
Adoption of Commercial Gene Expression Testing for Prostate Cancer Varies Among Regions
12/08/2020
12/08/2020
Journal of Clinical Pathways
News
FDA Approves Radioactive Diagnostic Agent for Prostate Cancer
12/01/2020
12/01/2020
Journal of Clinical Pathways
News
Darolutamide for Castration-Resistant Prostate Cancer Results in 5-Year Cost Savings
11/25/2020
11/25/2020
Journal of Clinical Pathways
Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer Treatment: An Interview With Joseph J. Busch, Jr., MD
Interview
Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer Treatment: An Interview With Joseph J. Busch, Jr., MD
04/18/2020

Ami Peltier

Ami Peltier
Dr Busch is the owner of the Busch Center, an imaging center in Alpharetta, Georgia that is dedicated to the diagnosis and treatment of prostate cancer. He spoke with IO Learning about integrating the recently FDA-approved TULSA...
Dr Busch is the owner of the Busch Center, an imaging center in Alpharetta, Georgia that is dedicated to the diagnosis and treatment of prostate cancer. He spoke with IO Learning about integrating the recently FDA-approved TULSA...
Dr Busch is the owner of the...
04/18/2020
IO Learning

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Psych Congress Regionals
July 18 ⁠–⁠ July 19
Advances in Inflammatory Bowel Disease Regionals
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
August 16 ⁠–⁠ August 18
APP Institute Dermatology
August 16 ⁠–⁠ August 17
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use